Philippe Crine has over 30 years experience in protein engineering and molecular endocrinology.
As cofounder and chief scientific officer of Enobia Pharma, Dr. Crine was responsible for development of new tharapies for rare bone metabolic diseases. Notably, Dr. Crine was responsible for the initiation and preclinical development of the asfotase alfa (now Strensiq®) prior to Enobia’s acquisition by Alexion. In 2015 Strensiq received worldwide marketing approval for hypophosphatasia, an ultra-rare metabolic bone disease.
Both prior to and simultaneously with the creation of Enobia, Dr. Crine also served as full professor at the Université de Montréal Medical School, chair of the Biochemistry department and finally assistant dean for Medical Research. Under his tenure the Biochemistry department recruited four new faculty and created a structural biology group jointly with McGill University and the National Research Council of Canada.
Dr. Crine received his Ph.D from the Université de Montréal Medical School and postdoctoral training at Brandeis University (Massachusetts) and at the Clinical Research Institute of Montreal. He co-authored over 120 publications in peer reviewed scientific journals.
Mr. Youssef Lemgendez has over 25 years of experience in the banking and investment sectors, acquired within major financial institutions. He joined the Solidarity Fund QFL in 2012, where he continues to work as Investment Manger, in the Life Sciences sector. He holds a master’s degree in business administration (MBA), business and project finance option, as well as a graduate diploma in management accounting (DESS), obtained at the School of Management Sciences at UQAM. Mr. Lemgendez also holds the title of Chartered Professional Accountant (CPA).
Richard Labaudinière is an experienced pharmaceutical scientist and executive with over 30 years experience in Senior leadership positions in Pharma and Biotech, most recently as CEO of FoldRx Pharmaceuticals, Inc.
Dr. Labaudinière has discovered and developed several drugs in different therapeutic areas. Under his leadership, FoldRx Pharmaceuticals, Inc. developed the drug, tafamidis (Vyndaqel®), a disease modifying therapy for the treatment of transthyretin-related hereditary amyloidosis, a rare but deadly neurodegenerative disease. FoldRx was acquired by Pfizer in 2010. At Glaxo, he led the preclinical program to discover, optimize and develop the PDE5 enzyme inhibitor tadalafil (Cialis®, Adcirca®) currently used for the treatment of erectile dysfunction (ED), of pulmonary arterial hypertension, and symptoms of benign prostatic hyperplasia (BPH).
Dr. Labaudinière has a PhD’s degree in organic chemistry from “Ecole Nationale Supérieure de Chimie de Montpellier” in France.
Robert McNeil has over 35 years of experience as an active investor and management participant in seed and early-stage life science companies. He founded Sanderling Ventures in 1979 and has served since then as managing director of Sanderling’s seven investment partnerships.
Previously, Sanderling Ventures was the seed investor for several companies that became the corner stones in the practice of modern medicine, including Advanced Cardiovascular Systems (the basis of Guidant Corp.) ,Ventritex (the basis of rhythm management at St. Jude Medical) Torax and several biotech pharma companies such as Regeneron, Intermune and Pacira . His ability to develop a close relationship with management and careful understanding of the companies’ technologies has allowed successful development of products at very early stage.
Dr. McNeil earned his Ph.D. in the fields of molecular biology, biochemistry and genetics from the University of California, Irvine.
Laurence Terrisse Rulleau, is currently a Partner at CTI Life Sciences Fund. Previously, Dr. Rulleau served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years. She worked at different firms including Desjardins securities, Yorkton securities and Blackmont securities. In her experience as an analyst, she researched over 100 life sciences companies with scientific due diligence on these companies as well as market analysis and competition assessment. Dr. Rulleau was ranked the number one Canadian life sciences analyst by the Starmine survey (a Thomson Reuters Company) and number one independent analyst by Brendon Wood survey.
Dr. Rulleau was involved in numerous mergers and acquisitions as well as IPOs. Dr. Rulleau was also CEO of HLA-G Technologies a biotechnology start-up based in France and more recently she served as Vice-President Business Development of Univalor, the technology transfer office of Montreal’s university and affiliated schools. Under her responsibility at Univalor in the last 3 years, more than 40 licences with the industry were signed and 8 companies started.
Dr. Rulleau has a Masters in Biology from The Universite du Quebec a Montreal (UQAM) and a Ph.D. from Montreal University executed at Montreal Clinical Research Institute.
Eric In is based in Toronto and Principal at CIC Capital Ventures, the North American venture activities of Crédit Mutuel Equity, the private equity arm of Crédit Mutuel Alliance Fédérale, a major banking group in France and Europe. Eric has close to 10 years of experience in venture and growth capital, and business development in France and Canada mainly in technology, media and communications. Previously, he worked 8 years for Entrepreneur Venture, an entrepreneur led VC fund managing $500m. Eric invested in 26 companies mainly in technology and managed 4 exits. Among his top exit: Enovance a cloud company acquired for $C100m 14 months after the investment. Eric moved to Toronto in 2015 and launched the North American subsidiary of an enterprise security software and managed business development in Toronto and Montreal. Eric is passionate about innovation, growth and international development with extensive experience operating in multicultural environments.
Eric holds an engineering degree in computer science from ENSIIE and a post-graduate master of finance from ESSEC Business School.